T. Yoshino

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

May, 2025

T. Yoshino

Dec 9, 2024, 13:18 | Insight

Pembrolizumab vs chemotherapy in MSI-high or MMR-deficient metastatic colorectal cancer

Shivani Modi shared a post on X: "Talk of the town! KEYNOTE-177 trial shows mFU: 73.3…

Dec 5, 2024, 15:37 | Insight

Two top-cited 2023 papers on Annals Of Oncology - ESMO

ESMO shared on LinkedIn: "As Annals Of Oncology 35th Anniversary is commemorated, here are two…

Dec 5, 2024, 09:26 | Blog

Pembrolizumab versus chemotherapy in MSI or dMMR metastatic colorectal cancer

Arndt Vogel shared on X: "Pembrolizumab versus chemotherapy in MSI or dMMR mCRC 5-year follow-up from…

Dec 4, 2024, 17:11 | Opinion

Iván R. González: Results from KEYNOTE-177 after 5 years by Thierry André et al.

Iván R. González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared on…

All: 4 Posts: 1 - 100

'

Who From Oncology is Featured in TIME100 Health 2025?

'

Francesco Acerbi and Testicular Cancer: The Defender's Fight and Triumphant Return to Football

'

Yvonne Award for Breakthrough Research 2024 Recipient to Time100 Health List

'

Dr Saunthari Somasundaram is the new President-Elect of the NCD Alliance

'

Does Plastic Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023